Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience
- DOI
- 10.1016/j.jtocrr.2026.101056
- Published
- 2026-10
- Container
- JTO Clinical and Research Reports
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2026.101056,
title = {Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience},
author = {Kevin Yijun Fan and Michelle Ku and Beatriz Jimenez Munarriz and Tracy Stockley and Andrew Rabinovitch and Geoffrey Liu and Penelope Bradbury and Natasha B. Leighl},
year = {2026},
journal = {JTO Clinical and Research Reports},
doi = {10.1016/j.jtocrr.2026.101056},
url = {https://doi.org/10.1016/j.jtocrr.2026.101056}
}RIS
TY - JOUR TI - Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience AU - Kevin Yijun Fan AU - Michelle Ku AU - Beatriz Jimenez Munarriz AU - Tracy Stockley AU - Andrew Rabinovitch AU - Geoffrey Liu AU - Penelope Bradbury AU - Natasha B. Leighl PY - 2026 JO - JTO Clinical and Research Reports DO - 10.1016/j.jtocrr.2026.101056 UR - https://doi.org/10.1016/j.jtocrr.2026.101056 ER -
APA
Fan, K. Y., Ku, M., Munarriz, B. J., Stockley, T., Rabinovitch, A., Liu, G., Bradbury, P., & Leighl, N. B. (2026). Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience. JTO Clinical and Research Reports. https://doi.org/10.1016/j.jtocrr.2026.101056
Source records
- crossref · retrieved 2026-09-25T11:58:07.036Z